Ibrahim Khalid S, Kheirallah Khalid A, Mayyas Fadia A, Alwaqfi Nizar R, Alawami Murtada H, Aljarrah Qusai M
Division of Cardiac Surgery, Department of General Surgery and Urology, College of Medicine, Jordan University of Science and Technology and Princess Muna Center for Heart Diseases and Surgery, King Abdullah University Hospital, Jordan.
Department of Public Health and Community Health, College of Medicine, Jordan University of Science and Technology, Jordan.
Ann Med Surg (Lond). 2021 Jan 26;62:395-401. doi: 10.1016/j.amsu.2021.01.077. eCollection 2021 Feb.
Valve replacement surgeries holds risks of morbidity and mortality.
The study cohort included 346 patients who underwent different types of valve surgery, excluding redo and Bentall operations. All operations were performed through a median sternotomy using cardiopulmonary bypass.
Mean patient age was 51.6 ± 16.1 years, and 51% were male. Approximately 21% had diabetes, and 44.6% were hypertensive. Aortic valve replacement (AVR) was performed in 125 patients (37%), mitral valve replacement (MVR) in 95 (28%), combined AVR and MVR in 42 (13%), AVR plus coronary artery bypass grafting (CABG) in 19 (6%), and MVR plus CABG in 32 (10%). Operative mortality was 5.8% (n = 20). In the bivariate-level analysis, older age, operation type, hypertension, emergency surgery, use of a biological valve in the aortic or mitral position, pump time greater than 120 min, and aortic clamp time greater than 60 min were significant predictors of 30-day mortality. Use of medications stratified by duration (less than or more than a month) was also shown to be a predictor of mortality. Use of angiotensin-converting enzyme inhibitors, digoxin, beta-blockers, statins, and loop diuretics was associated with mortality. Older age, emergency/salvage surgery, use of beta-blockers for less than 1 month preoperatively, and use of a biological valve in the aortic position were significant and independent predictors of 30-day mortality.
Age, emergency valve surgery, use of a biological valve, use of beta-blockers for less than 1 month before surgery, type of surgery, EF<35%, pump time, and cross clamp time were all found to be independent predictors of mortality in patients undergoing valve surgery. Further prospective multicenter studies may be needed to provide a comprehensive assessment of mortality in patients undergoing valve surgery in Jordan.
瓣膜置换手术存在发病和死亡风险。
研究队列包括346例行不同类型瓣膜手术的患者,不包括再次手术和Bentall手术。所有手术均通过正中胸骨切开术并使用体外循环进行。
患者平均年龄为51.6±16.1岁,51%为男性。约21%患有糖尿病,44.6%患有高血压。125例患者(37%)行主动脉瓣置换术(AVR),95例(28%)行二尖瓣置换术(MVR),42例(13%)行AVR和MVR联合手术,19例(6%)行AVR加冠状动脉旁路移植术(CABG),32例(10%)行MVR加CABG。手术死亡率为5.8%(n = 20)。在双变量水平分析中,年龄较大、手术类型、高血压、急诊手术、在主动脉或二尖瓣位置使用生物瓣膜、体外循环时间大于120分钟以及主动脉阻断时间大于60分钟是30天死亡率的显著预测因素。按使用时间(少于或多于1个月)分层的药物使用情况也被证明是死亡率的预测因素。使用血管紧张素转换酶抑制剂、地高辛、β受体阻滞剂、他汀类药物和袢利尿剂与死亡率相关。年龄较大、急诊/挽救性手术、术前使用β受体阻滞剂少于1个月以及在主动脉位置使用生物瓣膜是30天死亡率的显著且独立的预测因素。
年龄、急诊瓣膜手术、生物瓣膜的使用、术前使用β受体阻滞剂少于1个月、手术类型、射血分数<35%、体外循环时间和阻断时间均被发现是瓣膜手术患者死亡率的独立预测因素。可能需要进一步的前瞻性多中心研究来全面评估约旦瓣膜手术患者的死亡率。